Home > π-Icosa™ AAV Serotype Screening Platform

π-Icosa™ AAV Serotype Screening Platform

With its proprietary π-Icosa™ High-capacity and High-precision AAV serotype screening platform PackGene aims to screen higher infective and higher tissue-specific AAV serotypes for clinical trial development, which can greatly reduce the dosage and production cost of AAV-based gene drug while increasing safety and efficacy.

Advantages:

  • Higher library capacity
  • Higher precision AAV-serotype screening
  • Improves the AAV targeting with the lower dosing to increase safety and efficacy

Interested in our AAV services? Please contact us for a free consultation or  submit a request for a quotation.

Intellectual property:

Three patents are pending.

Screen the tissue-targeting AAVs to improve the efficiency

  • Library>1 billion mutants
  • Screens efficient AAVs which specifically target muscle, brain, etc.